In our study, the GSI RO4929097 specifically targets NOTCH4 cleavage in anti-estrogen-treated cells and, thus, decreases BCSC activity in vitro (MFE and ALDH activity) and tumor initiation in vivo. This evidence concerns the gene NOTCH4 and neoplasm.